What Researchers Did
Researchers conducted a double-blind randomized phase II study to evaluate hyperbaric oxygen therapy in 34 patients with radiation-induced brachial plexopathy, using warm sensory threshold as the primary endpoint.
What They Found
No statistically significant differences in the primary endpoint (warm sensory threshold) were observed between the hyperbaric oxygen and control groups up to 12 months post-treatment. However, normalization of the warm sensory threshold was reliably recorded in two patients receiving hyperbaric oxygen, and two other patients with chronic arm lymphedema reported major improvements in arm volume for at least 12 months.
What This Means for Canadian Patients
For Canadian patients with radiation-induced brachial plexopathy, hyperbaric oxygen therapy does not appear to significantly improve the primary symptom of sensory loss. However, it might offer some benefit for specific symptoms like lymphedema or in a small subset of patients, warranting further investigation.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada nor involved Canadian researchers or participants.
Study Limitations
A limitation of this phase II study is its small sample size (34 patients), which may have limited the power to detect statistically significant differences for the primary endpoint.